Article Text

Download PDFPDF

FRI0275 Systemic lupus erythematosus patients with positives autoantibodies with remission or low activity exhibit both lower interferon alpha and interleukin-10 levels
  1. E Grau Garcia1,
  2. FM Ortiz-Sanjuan1,
  3. M Fernandez Matilla2,
  4. CM Feced Olmos1,
  5. E Sánchez Labrador1,
  6. N Fernández-Llanio2,
  7. I Chalmeta Verdejo1,
  8. K Arévalo Ruales1,
  9. R Negueroles Albuixech1,
  10. J Ivorra Cortes1,
  11. JJ Fragio Gil1,
  12. I Martínez Cordellat1,
  13. R Mazarío González1,
  14. L Gonzalez Puig1,
  15. C Alcañiz Escandell1,
  16. C Nájera Herranz1,
  17. I Cánovas Olmos1,
  18. E Vicens Bernabeu1,
  19. JE Oller Rodriguez1,
  20. JA Castellano Cuesta2,
  21. V Fornés Ferrer3,
  22. D Marín Hervás3,
  23. JA Román Ivorra1
  1. 1Rheumatology Department, HUP la Fe
  2. 2Rheumatology Section, Hospital Arnau de Vilanova
  3. 3Biostatistics Unit, IIS la Fe, Valencia, Spain


Background Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption, including T and B cell activation and upregulation of autoantibody and immunocomplexes production that could damage different organs. Sometimes, patients with positives autoantibodies and serological manifestations show low disease activity or clinical remission. There is not enough information about persistent positive autoantibodies in absence of clinical activity neither the role of proinflamatory cytokines in this context.

Objectives To assess the clinical and molecular differences in SLE patients with positives autoantibodies and with low clinical activity or in clinical remission compared to the group with clinical activity.

Methods A cross-sectional, observational study of patients diagnosed of SLE according to SLICC 2012 criteria was performed. In these patients a complete blood-test was made, and clinical data by personal interview was collected. We analyzed the serum concentration of IL10, BLyS and INF1A by colorimetric methods. Biostatistical analysis was performed with R 3.3.2.

Results We selected 130 SLE patients with serological manifestations (defined by RELESSER study) out of 142 SLE patients. 91 cases showed low activity or remission (SLEDAI<6) and 39 presented moderate or high activity (SLEDAI>6). SLE patients with positives autoantibodies without clinical activity showed significantly lower anti-dsDNA levels (P=0.006), lower complement consumption (P=0.003) and lower accumulated damage evaluated by SLICC score (P=0.041). No differences on time of evolution in both groups were observed. In addition, SLE patients with positives autoantibodies without clinical activity exhibit significantly lower levels of IL10 (P<0.001) and INF1A (P=0.019). No differences on BLyS levels in both groups were observed. Finally, SLE patients with positives autoantibodies with clinical activity present more mucocutaneous lesions (P=0.014), musculoskeletal manifestations (P=0.004), neuropsychiatric manifestations (P=0.002), renal manifestations (P<0.001) and lymphopenia (P=0.008) than patients with positives autoantibodies and without clinical activity.

Conclusions In our series of SLE patients with both serological manifestations and low clinical activity have lower levels of IL10 and INF1A, compared to patients with high clinical activity. This result would suggest that differences in the cytokine levels are not related to autoantibodies presence but there are other mechanisms involved in cytokine production that would also be involved in maintenance of clinical remission.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.